<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">8513649</PMID>
      <DateCompleted>
        <Year>1993</Year>
        <Month>07</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0312-5963</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>24</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>1993</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical pharmacokinetics</Title>
          <ISOAbbreviation>Clin Pharmacokinet</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Clinical pharmacokinetics of alprazolam. Therapeutic implications.</ArticleTitle>
        <Pagination>
          <StartPage>453</StartPage>
          <EndPage>471</EndPage>
          <MedlinePgn>453-71</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Alprazolam is a triazolobenzodiazepine that is extensively prescribed in the Western world for the treatment of anxiety and panic disorders. Its benzodiazepine receptor binding characteristics are qualitatively similar to those of other benzodiazepines. The drug is metabolised primarily by hepatic microsomal oxidation, yielding alpha-hydroxy- and 4-hydroxy-alprazolam as principal initial metabolites. Both have lower intrinsic benzodiazepine receptor affinity than alprazolam and appear in human plasma at less than 10% of the concentrations of the parent drug. Plasma concentrations of the 4-hydroxy metabolite exceed those of the alpha-hydroxy derivative, but urinary recovery of alpha-hydroxy-alprazolam greatly exceeds that of 4-hydroxy-alprazolam. This may be explained by chemical instability of 4-hydroxy-alprazolam in vitro. After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg. Absolute bioavailability of oral alprazolam averages 80 to 100%. Pharmacokinetics are dose-independent and are unchanged during multiple-dose treatment. On average, mean steady-state plasma alprazolam concentrations change by 10 to 12 micrograms/L for each daily dosage change of 1 mg/day. Most studies show that alprazolam pharmacokinetics are not significantly influenced by gender. Clearance of alprazolam is reduced in many elderly individuals, even those who are apparently healthy. Clearance is significantly reduced in patients with cirrhosis. Renal disease causes reduced plasma protein binding of alprazolam (increased free fraction) and some data suggest reduced free clearance of alprazolam in such patients. Pharmacokinetics of alprazolam are not significantly altered in abstinent alcoholics or patients with panic disorder, and are not influenced by the phase of the menstrual cycle in women. Coadministration of cimetidine, fluoxetine, fluvoxamine or propoxyphene significantly impairs alprazolam clearance. However, alprazolam clearance is not altered by coadministration of propranolol, metronidazole, disulfiram, oral contraceptives or ethanol. Imipramine clearance may be impaired if alprazolam is coadministered. Alprazolam does not alter the pharmacokinetics of digoxin. Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L. Concentrations higher than this may be needed for suppression of the actual panic attacks. Side effects associated with alprazolam (drowsiness, sedation, etc.) are consistent with its primary benzodiazepine agonist action and increase in frequency with higher steady-state plasma concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Greenblatt</LastName>
            <ForeName>D J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wright</LastName>
            <ForeName>C E</ForeName>
            <Initials>CE</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>AG-00106</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DA-05258</GrantID>
            <Acronym>DA</Acronym>
            <Agency>NIDA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>MH-34223</GrantID>
            <Acronym>MH</Acronym>
            <Agency>NIMH NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Switzerland</Country>
        <MedlineTA>Clin Pharmacokinet</MedlineTA>
        <NlmUniqueID>7606849</NlmUniqueID>
        <ISSNLinking>0312-5963</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YU55MQ3IZY</RegistryNumber>
          <NameOfSubstance UI="D000525">Alprazolam</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000525" MajorTopicYN="N">Alprazolam</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>91</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1993</Year>
          <Month>6</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1993</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1993</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">8513649</ArticleId>
        <ArticleId IdType="doi">10.2165/00003088-199324060-00003</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Mol Pharmacol. 1989 Jul;36(1):89-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2787473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 1992 Nov;149(11):1556-62</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1415824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1990;100(4):477-84</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2320708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1990 Jun;10(3):157-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2376617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 1984 Feb;27(2):132-47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6141930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Anal Toxicol. 1985 Sep-Oct;9(5):207-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2865403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neuropharmacology. 1990 Mar;29(3):237-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1691458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychiatry. 1988 Sep;49(9):333-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3417618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Gen Psychiatry. 1993 Sep;50(9):715-22</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8357297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int Clin Psychopharmacol. 1990 Apr;5(2):111-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2199575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharm Pharmacol. 1983 Aug;35(8):524-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6137541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1991 Feb;11(1):48-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2040715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Psychiatr Res. 1990;24 Suppl 2:73-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1980702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr. 1990 Nov 30;533:97-110</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2081783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1988 Sep;44(3):326-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3138056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1984 Feb-Mar;24(2-3):113-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6143766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1988 May;28(5):454-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3392243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharm. 1983 Mar-Apr;2(2):139-43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6883942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Anal Toxicol. 1991 Jan-Feb;15(1):25-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2046338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1985 Nov;38(5):595-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2865030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1989 Jun;29(6):543-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2754023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 1984 Mar-Apr;9(2):177-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6143633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1987 Oct;42(4):433-41</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3665341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Clin Pharmacol. 1990;39(1):21-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2276384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 1989 Mar;16(3):180-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2721087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr. 1990 Dec 14;534:202-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2094707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 1985 Jan;19(1):51-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2858217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1984;84(4):452-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6152055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1984 Nov;36(5):683-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6149030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr. 1988 Aug 19;430(1):180-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3215955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1988 Mar;28(3):240-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3360972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharmacol Exp Ther. 1991 Mar;256(3):897-901</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1848631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1991 Oct;50(4):404-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1914376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biochem Pharmacol. 1989 Nov 1;38(21):3773-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2557030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1987;91(2):168-74</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2883695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1988 Mar;43(3):270-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3345619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr. 1991 Jul 17;568(1):253-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1770105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1984 Sep;36(3):379-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6147221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Anal Toxicol. 1987 Nov-Dec;11(6):263-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3323671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1983;80(3):275-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6137021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Chem. 1984 Oct;30(10):1652-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6478595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ther Drug Monit. 1989 Nov;11(6):652-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2512694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Gen Psychiatry. 1990 Oct;47(10):899-907</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2222129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1989 Nov;46(5):552-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2684474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Am J Psychiatry. 1984 Dec;141(12):1612-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6150651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ther Drug Monit. 1988;10(2):231-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3381243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Biochem Behav. 1988 Jun;30(2):511-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2845448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biomed Environ Mass Spectrom. 1986 Mar;13(3):129-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2938652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1991;104(3):323-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1924640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1986 Oct;6(5):292-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3771810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1984 Oct;36(4):451-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6434219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Anal Toxicol. 1987 Nov-Dec;11(6):247-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3431092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1987;93(1):105-12</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3114808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anal Chem. 1984 Aug;56(9):1590-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6486443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1992 May;51(5):533-40</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1587068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharm Pharmacol. 1982 Feb;34(2):115-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6121870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacokinet. 1991 Sep;21(3):165-77</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1684924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Toxicol. 1991 Feb;68(2):121-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1852717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acta Pharm Nord. 1991;3(4):249-50</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1781916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacotherapy. 1982 Sep-Oct;2(5):243-54</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6133268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1991 Jun;31(6):571-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1880224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1987;93(1):72-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2888155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1988;96(3):365-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3146770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Neurochem. 1987 Nov;49(5):1595-601</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2889803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1986 Apr;26(4):292-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2871050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1983 Dec;3(6):366-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6643703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1991;104(1):103-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1881994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Pharm Pharmacol. 1983 Mar;35(3):179-80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6132978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Gen Psychiatry. 1983 Mar;40(3):287-90</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6131657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Pharmacol. 1991 Jun;31(6):492-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1652596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1990 Feb;10(1):27-32</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2407754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Clin Pharmacol. 1990;38(2):157-60</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2338112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arch Gen Psychiatry. 1990 Oct;47(10):908-15</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2222130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Clin Psychopharmacol. 1987 Oct;7(5):332-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3680603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Int J Clin Pharmacol Ther Toxicol. 1985 Aug;23(8):447-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2864320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur J Clin Pharmacol. 1992;42(4):439-43</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1516609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>J Chromatogr. 1981 Sep 11;225(1):202-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6117563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biopharm Drug Dispos. 1990 Jan-Feb;11(1):31-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2322635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Psychopharmacology (Berl). 1985;86(4):392-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2863843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Biochem Behav. 1990 Oct;37(2):365-70</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1964224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Pharmacol Ther. 1992 Nov;52(5):479-86</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1424422</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
